Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease.

Abstract

BACKGROUND AND AIMS:

Limited data are available regarding the pulmonary toxicity of anti-tumour necrosis factor (anti-TNF) therapy for inflammatory bowel disease (IBD).

METHODS:

We retrospectively searched the IBD registry of Asan Medical Center in order to identify patients with lung injury following anti-TNF therapy.

RESULTS:

Among 1002 patients who were treated using anti-TNF therapy, six cases (0.6%) of anti-TNF-induced lung injury (ATILI) were identified. ATILI was observed soon after the beginning of anti-TNF therapy (two to four doses of anti-TNF). All of these patients experienced improvements in their respiratory symptoms and radiographic findings once the anti-TNF therapy was discontinued. One patient who suffered ATILI following adalimumab was switched to subsequent infliximab and was without recurrence of ATILI.

CONCLUSION:

Clinicians should be vigilant regarding the possibility of ATILI in IBD patients treated with anti-TNF agents.

• Authors: Ho-Su Lee, Kyung-Wook Jo, Tae Sun Shim, Jin Woo Song, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Jin-Ho Kim, Suk-Kyun Yang
• Journal: Journal of Crohn's & colitis (J Crohns Colitis) Vol. 9 Issue 11 Pg. 1053-7 (Nov 2015) ISSN: 1876-4479 [Electronic] England
• PMID: 26221002 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].

Chemical References

• Gastrointestinal Agents
• Infliximab
• Adalimumab

Topics

• Adalimumab (adverse effects, therapeutic use)
• Adult
• Aged
• Female
• Follow-Up Studies
• Gastrointestinal Agents (adverse effects, therapeutic use)
• Humans
• Inflammatory Bowel Diseases (complications, drug therapy)
• Infliximab (adverse effects, therapeutic use)
• Lung Injury (chemically induced, diagnosis)
• Male
• Middle Aged
• Retrospective Studies
• Treatment Outcome